open label

DRUG5 trials

Sponsors

XenoPort, Inc., GW Research Ltd, Pfizer, Cellestia Biotech AG, University of Washington

Conditions

HIV/AIDSHealthy VolunteerPharmacokineticschildepilepsy dravet syndrome and lennox gastaut syndromeinflammation of the intestine inflammatory bowel disease (IBD)metastatic solid tumours and haematological malignancies characterised by alterations of the NOTCH signalling pathway advanced or metastatic solid tumours and haematological malignancies

Phase 1

Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)

CompletedNCT00833391

XenoPort, Inc.Healthy Volunteer, Pharmacokinetics

Start: 2009-01-31End: 2009-03-31Updated: 2013-05-14

Phase 2

A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN-LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY,TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Active, not recruitingNL-OMON47159

Pfizerinflammation of the intestine inflammatory bowel disease (IBD)

Start: 2017-10-30Target: 4Updated: 2024-02-28

Phase 3

An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes

Active, not recruitingNL-OMON45127

GW Research Ltdchildepilepsy dravet syndrome and lennox gastaut syndrome

Start: 2015-10-01Target: 40Updated: 2024-02-28

Phase 4

Partners Scale-Up Project (PSUP)

Active, not recruitingPACTR202003743599701

University of WashingtonHIV/AIDS

Start: 2017-02-06Target: 2400Updated: 2026-08-03

Unknown Phase

A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients with Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway

Cellestia Biotech AGmetastatic solid tumours and haematological malignancies characterised by alterations of the NOTCH signalling pathway advanced or metastatic solid tumours and haematological malignancies

Target: 33Updated: 2024-02-28